V18N127 PCTDIV 2ND · 2015. 12. 1. · [57] Abstract: Methods for preparing monomeric cyto toxic drug/carrier conjugates with a drug loading significantly higher than in previously

Intellectual Property Center, 28 Upper McKinley Rd. McKinley Hill Town Center, Fort Bonifacio, Taguig City 1634 Philippines

Tel. No. 238-6300 Website: http://www.ipophil.gov.ph e-mail: [email protected]

Volume 18 Number 127 Date Released: December 02, 2015

Divisional Applications of National Phase Entry Applications

1 INVENTION

[19] INTELLECTUAL PROPERTY PHILIPPINES

[12] INVENTION PUBLICATION

[21] Application Number: 1/2013/501128 Document Code:

A1

[86] International Application No.

PCT/US2008/081516 [22] Int’l Filing Date: 29/10/2008

[87] International Publication No.

WO2009/058812 A1 [43] International Publication Date:

07/05/2009

[85] National Phase Entry Date:

03/06/2013

[60] Division of: 1/2010/500924 filed on 27 April 2010

[54] Title: ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY

[71] Applicant(s): GENENTECH, INC. [US]

[72] Inventor(s): LEBRETON, BENEDICTE ANDREE[FR]: O'CONNOR, DEBORAH ANN[US]: SAFTA, AURELIA[US]: SHARMA, MANDAKINI[IN]

[73] Assignee(s): NONE

[74] Attorney / Agent: HECHANOVA AND CO. INC.

[30] Priority Data: 60/983,825 30/10/2007 US

[51] International Class 8: C 07K 1/18, 16/06, 16/22, 16/28

[57] Abstract:

A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.

Representative Drawing(s):

Relevant docs:

Category Document description Relevant to claim

No.

Document No.

X

WO 02/096457 A (Novartis-Erfindungen Verwaltungsgesellschaft M. B. H.) 5 December 2002

1-2 1

X WO 2004/001007 A (IDEC Pharmaceutical Corporation) 31 December 2003

1-2 2

X WO 2005/066139 A (Millenium Pharmaceuticals, Inc.) 21 July 2005

1-2 3

X WO 2005/115453 A (Genentech, Inc.)

1-2 4







A1





13/11/2003


06/06/2013

[60] Division of: 1/2004/501761 filed on 2 November 2004

[54] Title: CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES

[71] Applicant(s): WYETH HOLDINGS CORPORATION [US]

[72] Inventor(s):

KUNZ, ARTHUR[US]: MORAN, JUSTIN, KEITH[US]: RUBINO, JOSEPH, THOMAS[US]: JAIN, NEERA[CA]: VIDUNAS, EUGENE, JOSEPH[US]: SIMPSON, JOHN, MCLEAN[US]: ROBBINS, PAUL, DAVID[US]: MERCHANT, NISHITH[US]: DIJOSEPH, JOHN, FRANCIS[US]: RUPPEN, MARK, EDWARD[US]: DAMLE, NITIN, KRISHNAJI[US]: POPPLEWELL, ANDREW, GEORGE[GB]


[74] Attorney / Agent: CASTILLO LAMAN TAN ET. AL.

[30] Priority Data: 60/377,440 02/05/2002 US

[51] International Class 8: A 61K 41/00, 47/48

[57] Abstract:

Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.


Relevant docs:


No.

Document No.

Y US 5 712 374 A (Kuntsmann, et. al.) 27 January 1998

1-58 1

Y US 6 183 744 B1 (Goldenberg) 06 February 2001

1-58 2

Y WO 91/09967 A1 (Celltech Limited) 11 July 1991

1-58 3

Y

Yelton, et. al. "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis." THE JOURNAL OF IMMUNOLOGY, 1995, vol. 155 , pages 1994-2004

1-58 4

Y

Ghetie M. A., et. al. "Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins, etc." CANCER RESEARCH 1 Nov 1991 LNKD-Pubmed 1933855, vol. 51, no. 21, 1 November 1991, pages 5876-5880

1-58 5







A1





16/04/2009


08/07/2013

[60] Division of: 1/2010/500727 filed on 5 April 2010

[54] Title: USE OF ANTI~AMYLOID BETA ANTIBODY

[71] Applicant(s): AC IMMUNE S.A. [CH] and GENENTECH, INC. [US]

[72] Inventor(s): PFEIFER, ANDREA[DE]: MUHS, ANDREAS[DE]: WATTS, RYAN[US]


[74] Attorney / Agent: E. B. ASTUDILLO & ASSOCIATES

[30] Priority Data: 60/960,614 05/10/2007 US and 60/960,615 05/10/2007 US

[51] International Class 8: C 07K 16/00

[57] Abstract:

The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of ß-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.


Relevant docs:


No.

Document No.

X WO 2007/068412 A (AC Immune SA, et. al.) 21 June 2007

1-62 1

X

Ding, et. al. "Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta, etc." VISION RESEARCH, PERGAMON, PRESS, OXFORD, GB, vol. 48, no. 3, 20 September 2007, pages 339-345

1-62 2

X WO 2006/039327 A (Merck & Co., Inc., et. al.) 13 April 2006

1-69 3

X

Guo Li, et. al. "Targeting amyloid-beta in glaucoma treatment." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASINGTON DC, US, vol. 104, no. 33, 1 August 2007, pages 13444-13449

1-69 4

X

McKinnon S. J., et. al. "Caspase activation and amyloid precursor protein, etc." INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 43, no. 4, 1 January 2002, pages 1077-1087

1-69 5







A1


PCT/EP2006/050489 [22] Int’l Filing Date: 27/01/2006



03/08/2006


28/08/2013

[60] Division of: 1/2007/501571 filed on 23 July 2007

[54] Title: PLANTS HAVING INCREASED YIELD AND A METHOD FOR MAKING THE SAME

[71] Applicant(s): CROPDESIGN N.V. [BE]

[72] Inventor(s): FRANKARD, VALERIE[BE]


[74] Attorney / Agent: E.B. ASTUDILLO AND ASSOCIATES

[30] Priority Data: 05100537.9 27/01/2005 EP; 60/649,041 01/02/2005 US and 60/730,403 26/10/2005 US

[51] International Class 8: A 01H 5/00, C 12N 15/82

[57] Abstract:

The present invention concerns a method for increasing plant yield by modulating expression in a plant of a nucleic acid encoding a synovial sarcoma translocation (SYT) polypeptide or a homologue thereof. One such method comprises introducing into a plant a SYT nucleic acid or variant thereof. The invention also relates to transgenic plants having introduced therein a SYT nucleic acid or variant thereof, which plants have increased yield relative to corresponding wild type plants. The present invention also concerns constructs useful in the methods of the invention.


Relevant docs:


No.

Document No.

X

Patent Abstracts of Japan vol. 2003, no. 12, 5 December 2003 & JP 2004 350553 A (Japan Science & Technology Agency), 16 December 2004

1-35 1

X

Jeong Hoe Kim, et. al. "The ATGRF family of putative trranscription factors is involved in leaf and cotyledon growth in arabidopsis." PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 36, no. 1 October 2003, pages 94-104

1-35 2

X

Jeong Hoe Kim, et. al. "A transcriptional coactivator, AtGIF1, is involved in regulating leaf growth and morphology in Arabidopsis." PNAS, Wahington DC, US, vol. 101, no. 36, 7 September 2004 pages 13374-13379

1-35 3

X

Kim J-H. et. al. "Studies on the function of OSGRF1-like (ATGRL) genes in Arabidopsis" PLANT BIOLOGY, New York, NY, US, August 2002, page 56

1-35 4







A1





16/10/2008


09/09/2013

[60] Division of: 1/2009/501801 filed on 22 September 2009

[54] Title: BIOLOGICAL-BASED CATALYST TO DELAY PLANT DEVELOPMENT PROCESSES

[71] Applicant(s): GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. [US]

[72] Inventor(s): PIERCE, GEORGE E.[US]: GANGULY, SANGEETA[IN]: DRAGO, GENE K.[US]


[74] Attorney / Agent: FEDERIS AND ASSOCIATES LAW OFFICES

[30] Priority Data: 11/695,377 02/04/2007 US

[51] International Class 8: A 01N 63/00, A 01P 21/00

[57] Abstract:

The present invention is directed to methods for delaying a plant development process comprising exposing a plant or plant part to one or more bacteria or enzymes. In specific embodiments, the one or more bacteria are selected from the group consisting of Rhodococcus spp., Pseudomonas chloroaphis, Brevibacterium ketoglutamicum, and a mixture comprising any combination of these bacteria. Apparatuses for delaying a plant development process comprising a catalyst that comprises one or more of the above bacteria.


Relevant docs: Category Document description

Relevant to claim

No.

Document No.

X Andrew J. Reed, et. al. "Delayed ripening tomato plants

1-15 1

expressing, etc." JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 43, 1995, pages 1954-1962

X

Kozdroj J., et. al. "Influence of introduced potential biocontrol agents on maize seedling growth, etc." SOIL BIOLOGY AND BIOCHEMISTRY, PERGAMON, OXFORD, GB, vol. 36, no. 11, 1 November 2004, pages 1775-1784

1-15 2

X WO 92/12249 A (Monsanto CO) 23 July 1992

1-15 3

Y

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; Kulikova, A. K., et. al. "Ehtylene epoxidation by native and immobilized cells, etc." retrieved from STN Database accession no. 2000:107646

1-15 4

Y

Nagasawa, T., et. al. "Optimum culture conditions for the production of cobalt-containing nitrile, et. al." APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 34, no. 6, 1 March 1991, pages 783-788

1-15 5







A1


PCT/EP2007/058049 [22] Int’l Filing Date: 03/08/2007



14/02/2008


02/10/2013

[60] Division of: 1/2010/500267 filed on 2 February 2010

[54] Title: GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF

[71] Applicant(s): BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]

[72] Inventor(s): BELLGARD, MATTHEW[AU]: HAMPSON, DAVID JOHN[AU]: LA, TOM[AU]


[74] Attorney / Agent: MANUEL C. CASES, JR. AND ASSOCIATES

[30] Priority Data: 2006904311 09/08/2006 AU

[51] International Class 8: A 61K 39/02, 39/40, 48/00, C 07K 14/20, C 12N 1/21, 15/31, 15/63, C 12Q 1/68, G 01N 33/569

[57] Abstract:

Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species, including B. intermedia, B. suantatina, B. alvinipulli, B. aalborgi, B. innocens, B. murdochii, and B. pilosicoli.

Representative Drawing(s): NONE

Relevant docs:

Category Document description Relevant to claim No.

Document No.

A WO 91/04036 A (ML Technology Ventures) 4 April 1991

1-44 1

A WO 2004/007726 A (Akzo Nobel NV, et. al.) 22 January 2004

1-44 2

A WO 03/095480 A (Akzo Nobel NV) 20 November 2003

1-44 3







A1





12/09/2008


11/11/2013

[60] Division of: 1/2009/501698 filed on 4 September 2009

[54] Title: VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF

[71] Applicant(s): AMGEN INC. [US]

[72] Inventor(s): SUN, JEONGHOON[KR]: TAM, LEI-TING TONY[US]: HAN, HQ[US]: KWAK, KEITH SOO-NYUNG[US]: ZHOU, XIAOLAN[US]


[74] Attorney / Agent: SAPALO VELEZ BUNDANG & BULILAN LAW OFFICES


[51] International Class 8: A 61K 38/17, C 07K 14/71, C 12N 15/12, 15/861, 5/10

[57] Abstract:

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.


Relevant docs:


Document No.

Y US 2004/223966 A1 (Wolfman Neil M., et. al.) 11 November 2004

1 1

Y WO 2006/020884 A (Wyeth Corp., et. al.) 23 February 2006

1 2

Y WO 2004/039948 A (Wyeth Corp., et. al.) 13 May 2004

1 3

Y US 2006/034831 A1 (Tobin James F.) 16 February 2006

1 4







A1




WO2009/046033A3 [43] International Publication Date:


22/11/2013

[60] Division of: 1/2010/500674 filed on 29 March 2010

[54] Title: SILICONE GEL~BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION

[71] Applicant(s): VALEANT PHARMACEUTICALS INTERNATIONAL [US]

[72] Inventor(s): PALEFSKY, IRWIN[US]: WILSON, NI'KITA[US]


[74] Attorney / Agent: HECHANOVA AND CO. INC.

[30] Priority Data: 60/997,166 30/09/2007 US

[51] International Class 8: A 61L 15/22, 15/60, C 08L 83/04

[57] Abstract: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.


Relevant docs:


Document No.

X WO 2004/006972A1 (BERLAT) 22 January 2004

1-30 1

Y US 2005/0100568 A1 (DE MUL ET AL) 12 May 2005

1-30 2







A1


PCT/JP2008/000290 [22] Int’l Filing Date: 21/02/2008



28/08/2008


17/07/2014

[60] Division of: 1/2009/501610 filed on 20 August 2009

[54] Title: PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS

[71] Applicant(s): ONCOTHERAPY SCIENCE, INC. [JP]

[72] Inventor(s): TSUNODA, TAKUYA[JP]: OHSAWA, RYUJI[JP]


[74] Attorney / Agent: SAPALO VELEZ BUNDANG & BULILAN LAW OFFICES

[30] Priority Data: 60/902,949 21/02/2007 US

[51] International Class 8: A 61K 38/00, A 61P 35/00, C 07K 11/00, 14/00, C 12N 5/10, G 01N 33/15, 33/50

[57] Abstract:

The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.


Relevant docs:


No.

Document No.

X

Takako Suda, et. al. "Identification of Secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray" CANCER SCIENCE, vol. 97, no. 5, 1 May 2006, pages 411-419

1-17 1

Harada M., et. al. "Kinesin superfamilt protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes, etc." ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 17, no. 3, 1 January 2007, pages 629-636

2

X WO 02/086443 A2 (EOS Biotechnology Inc., et. al.) 31 October 2002

1-17 3

X WO 2006/090810 A2 (Oncotherapy Science Inc., et. al.) 31 August 2006

1-17 4







A1


PCT/IB2010/000998 [22] Int’l Filing Date: 14/04/2010


WO 2010/119343 [43] International Publication Date:

21/10/2010


14/01/2015

[60] Division of: 1/2011/502036 filed on 7 October 2011

[54] Title: COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS

[71] Applicant(s): NOVARTIS AG [CH]

[72] Inventor(s): BAGNOLI, FABIO[IT]: BIAGINI, MASSIMILIANO[IT]: FIASCHI, LUIGI[IT]: GRANDI, GUIDO[IT]: MISHRA, RAVI[IT]: NORAIS, NATHALIE[IT]: SCARSELLI, MARIA[IT]


[74] Attorney / Agent: SYCIP, SALAZAR, HERNANDEZ AND GATMAITAN


[51] International Class 8: A 61K 39/085, C 07K 14/31

[57] Abstract:

An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S.aureus saccharides.


Relevant docs:


Document No.

X WO 02/094868 A2 (CHIRON SPA, IT) November 28, 2002

all 1







A1


PCT/JP2010/057196 [22] Int’l Filing Date: 16/04/2010



21/10/2010


03/02/2015

[60] Division of: 1/2011/502100 filed on 13 October 2011

[54] Title: PHARMACEUTICAL COMPOSITIONS

[71] Applicant(s): TAISHO PHARMACEUTICAL CO., LTD. [JP]

[72] Inventor(s): TAKAHASHI, TEISUKE[JP]: UCHIDA, SAEKO[JP]


[74] Attorney / Agent: CASTILLO LAMAN TAN PANTALEON & SAN JOSE LAW OFFICES

[30] Priority Data: 2009-100210 16/04/2009 JP

[51] International Class 8: A 61K 31/155, 31/382, 31/4439, 31/64, 45/00, A 61P 13/12, 25/00, 27/02, 3/10, 43/00, 5/50, 9/10, 9/14, C 07D 335/02

[57] Abstract:

A pharmaceutical composition comprising a combination of (A) a 1-thio-D-glucitol compound represented by the general formula (I) and (B) at least one member of the group consisting of biguanides, insulin secretagogues, insulin sensitizers, insulins, dipeptidyl peptidase IV inhibitors, a-glucosidase inhibitors, and GLP-1 mimetics, has superior efficacy in preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus and yet it causes no appreciable side effects.


Relevant docs:


No.

Document No.

X WO 2008/072726 A1 (TAISHO PHARMA CO., LTD) June 19, 2008

all 1

X JP 2008-31161 A (TAISHO PHARMA CO., LTD) February 14, 2008

all 2

X EP 2036901 A1 iTAISHO PHARMA CO., LTD) March 18, 2009

all 3

X EP 1845095 A1 (TAISHO PHARMA CO., LTD) October 17, 2007

all 4

Y US 2003/0064935 A1 (JACK Z. GOUGOUTAS) April 3, 2003

all 5

Y WO 2008/020011 A1 all 6

(BOEHRINGER INGELHEIM INTERNATIONAL GMBH) February 21, 2008







A1





25/06/2009


10/04/2015

[60] Division of: 1/2010/501330 filed on 9 June 2010

[54] Title: BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR

[71] Applicant(s): BRISTOL-MYERS SQUIBB COMPANY [US] and PFIZER INC [US]

[72] Inventor(s):

MIN, JING[US]: WU, YANLI[CA]: FINN, RORY, FRANCIS[US]: THIELE, BARRETT, RICHARD[US]: LIAO, WEI[US]: GLADUE, RONALD, PAUL[US]: RAJPAL, ARVIND[US]: PARADIS, TIMOTHY, JOSEPH[US]: BRAMS, PETER[DE]: DEVAUX, BRIGITTE[US]: WU, YI[US]: TOY, KRISTOPHER[US]: LEBLANC, HEIDI, N[CA]: HUANG, HAICHUN[US]


[74] Attorney / Agent: E.B. ASTUDILLO AND ASSOCIATES

[30] Priority Data: 61/013,947 14/12/2007 US

[51] International Class 8: A 61P 35/00, C 07K 16/28

[57] Abstract:

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells comtaining the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.


Relevant docs:


No.

Document No.

X WO 03/106498 A (CRUCELL HOLLAND BV, NL) December 24, 2003

all 1

X WO 99/42585 A (SISTERS OF PROVIDENCE IN OREGO, US) August 26, 1999

all 2

X

XIE F ET AL: "Characterization and application of two novel monoclonal antibodies against human OX40..." TISSUE ANTIGENS, April 2006, vol 67, no. 4, pp. 307-317, XP002525127.

all 3

X KJAERGAARD J ET AL: "Therapeutic efficacy of OX-40

all 4

receptor antibody depends on tumor immunogenecity and anatomic site of tumor growth" CANCER RES, Oct. 1, 2000, vol., 60, no. 19, pp. 5514-5521, XP007908325.

X

KJAERGAARD J ET AL: "Augmentation versus inhibition:..." J. IMMUNOLOGY, December 1, 2001, vol. 167, no. 11, pp. 6669-6677, XP007908324.

all 5

X

WEINBERG ANDREW D ET AL: "Anti-OX40 (CD134) administration to nonhuman primates..." J IMMUNOTHERAPY, vol. 29, no. 6, November 1, 2006, pp. 575-585, XP009115398

all 6

X WO 2007/062245 A (KIRIN BREWERY, JP) May 31, 2007

all 7

Documents

V18N127 PCTDIV 2ND · 2015. 12. 1. · [57] Abstract: Methods for preparing monomeric cyto toxic drug/carrier conjugates with a drug loading significantly higher than in previously